Compound ID | 1225
Synonym(s): ancremonam | LYS228 | BOS-228 | BOS228 | BOS-228 | BOS 228
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Penicillin binding protein inhibitor (PBP inhibitor) |
| Target Pathogen: | Active against Enterobacteriaceae |
| Description: | A monobactam; indicated for urinary tract infections and complicated intraabdominal infections |
| Institute where first reported: | Boston Pharmaceuticals (Licensed from Novartis AG) |
| Highest development stage: | Phase 2 |
| Development status: | Active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/118379834 |
| Guide to Pharmacology: | ancremonam |
| Citations: |
|